REWRITE THERAPEUTICS
Rewrite Therapeutics is a private biotechnology company focused on advancing novel DNA writing technologies.
REWRITE THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.rewritetherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF LetsEncrypt Amazon Google Apps For Business ASP.NET IIS IIS 10 Amazon Oregon Region Namecheap DNS
Current Employees Featured
Founder
Official Site Inspections
http://www.rewritetherapeutics.com
Unable to get host informations!!!
More informations about "Rewrite Therapeutics"
Rewrite Therapeutics - Crunchbase Company Profile
Rewrite Therapeutics is a private biotechnology company focused on advancing novel DNA writing technologies. Rewrite Therapeutics was acquired by Intellia Therapeutics on Feb 3, 2022. Where is Rewrite Therapeutics's headquarters? …See details»
Rewrite therapeutics Company Profile 2024: Valuation, …
Operator of a biotechnology company intended to create advanced novel DNA writing technologies. The company develops DNA polymerization technology that can target changes in genomes without making double-stranded breaks, …See details»
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
Feb 3, 2022 · Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategiesSee details»
Rewrite Therapeutics - Products, Competitors, Financials, …
Rewrite Therapeutics provides a genome editing technology that is deliverable with AAV and LNP, and can edit genomes in dividing and non-dividing cells. On February 3rd, 2022, Rewrite …See details»
Intellia Therapeutics Announces Acquisition of Rewrite
Feb 3, 2022 · Rewrite has developed promising new tools for genome editing, including DNA writing via CRISPR/Cas9-guided polymerases.See details»
Intellia Therapeutics acquires Rewrite Therapeutics - 2022-02-03 ...
Feb 3, 2022 · Rewrite Therapeutics Rewrite Therapeutics is a private biotechnology company focused on advancing novel DNA writing technologies. Acquiring Organization: Intellia …See details»
Rewrite Therapeutics | Intellectual Property & Industry …
Rewrite Therapeutics accelerates drug development using a proprietary CRISPR-based evolution platform. For more information, contact Shakked Halperin. Formerly known as Evolve Biotech, and Rewrite Biotech. The company was …See details»
Rewrite Therapeutics - LinkedIn
Rewrite Therapeutics | 236 followers on LinkedIn. Rewriting the treatment of genetic disease.See details»
Rewrite and Replace: Shakked Halperin, Serial …
In February 2022, Rewrite Therapeutics, founded by Shakked Halperin, PhD and known for its DNA-writing technology, was acquired by Intellia Therapeutics. But Shakked isn’t one to take it easy! Just a few weeks prior, he had already …See details»
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
Feb 3, 2022 · Rewrite has developed promising new tools for genome editing, including DNA writing via CRISPR/Cas9-guided polymerases.See details»
Intellia Therapeutics Acquires Rewrite Therapeutics - PharmTech
Feb 7, 2022 · Intellia Therapeutics announced on Feb. 3, 2022 that the clinical-state genome editing company was acquiring Rewrite Therapeutics, a biotechnology company that develops …See details»
Get Me (DNA) Rewrite: Intellia’s First Acquisition Expands CRISPR …
Feb 16, 2022 · Rewrite Therapeutics and its DNA-writing platform have been acquired for up to $200 million by Intellia Therapeutics, one of the biggest CRISPR-based genome editing …See details»
Intellia Expands Genome Editing Toolbox with Acquisition of …
Feb 3, 2022 · Genome editing biotech Intellia Therapeutics has acquired Rewrite Therapeutics, expanding its toolbox with a versatile DNA writing platform that complements its existing …See details»
Intellia Acquires Rewrite in Deal Worth Up to $200M
Feb 4, 2022 · Genome editing pioneer Intellia Therapeutics has acquired Rewrite Therapeutics, a little-known biotech developing new tools for genome editing, including DNA writing via …See details»
Intellia acquires DNA writing company Rewrite - Chemical
Feb 11, 2022 · Intellia Therapeutics has acquired Rewrite Therapeutics, a developer of DNA-writing technologies, for $45 million plus $155 million in potential milestone payments. Intellia …See details»
Wilson Sonsini Advises Rewrite Therapeutics on Its Acquisition by ...
Feb 3, 2022 · Wilson Sonsini Goodrich & Rosati advised Rewrite Therapeutics on IP, technology transactions, and antitrust matters related to the transaction. Rewrite has developed promising …See details»
Intellia Therapeutics Acquires Rewrite Therapeutics
Feb 7, 2022 · Intellia Therapeutics announced on Feb. 3, 2022 that the clinical-state genome editing company was acquiring Rewrite Therapeutics, a biotechnology company that develops …See details»
Intellia, expanding in gene editing, buys startup Rewrite for $45M
Feb 3, 2022 · Intellia Therapeutics, a leading developer of CRISPR-based medicines, on Thursday said it will buy privately held Rewrite Therapeutics for $45 million, as it seeks to …See details»
Intellia’s Rewrite Therapeutics buyout brings new precision to …
Feb 3, 2022 · Intellia Therapeutics has leveraged CRISPR technology to develop a pipeline of experimental gene-editing therapies, making headlines last year with early clinical data …See details»
Next-generation gene-editing platforms drive CRISPR deals - Nature
Feb 10, 2022 · Most notably, Pfizer partnered with Beam Therapeutics to collaborate on in vivo base editing programmes for a range of rare diseases. The first wave of CRISPR gene-editing …See details»